Jinfang Pharmaceutical's KRAS G12C inhibitors apply for clinical Amgen, Novartis and other corporate layouts

On May 26, according to the official website of CDE Jinfang Pharmaceutical, the clinical trial application of GFH925, a new class 1 drug, was accepted.

RAS is the first oncogene identified in human tumors, and it is also one of the most widespread oncogenic mutation genes.

KRAS gene mutations are mainly concentrated in the positions of codons 12, 13 and 61, of which mutations at codon 12 account for more than 80%, including G12A, G12C, G12D, G12R, G12S and G12V.

KRAS G12C mutations account for 12% of all KRAS mutations, and have different incidences in different cancers.

At present, no KRAS G12C targeted drug has been approved in the world, but many drugs are in clinical trials.

Research KRAS G12C inhibitor (incomplete statistics)

Sotorasib is the first small molecule KRASG12C inhibitor that successfully targets KRAS and enters human clinical development.

Adagrasib (MRTX849) was developed by Mirati Therapeutics.

LY3537982 is a new generation of KRAS G12C inhibitor developed by Eli Lilly.

ARS-3248 is a new generation of KRAS G12C inhibitor developed by Araxes (a subsidiary of Wellspring) based on ARS-1620.

BPI-421286 is a new type of potent and highly selective covalent irreversible KRAS G12C oral small molecule inhibitor developed by Betta Pharmaceuticals.

D-1553 is a KRAS G12C inhibitor independently developed by Yifang Bio.

JAB-21822 is a small molecule KRAS G12C inhibitor independently developed by Jacos Pharmaceuticals.

GH35 is the first clinical trial application submitted by Qinhao Pharmaceutical in China.

Since the discovery of the RAS gene in 1982, from what was initially thought to be unpreparable, to now the first drug was reported for production, and many drugs entered the clinical stage, scientists and companies have made too many unknown efforts and look forward to the first KRAS G12C inhibitor.

However, acquired resistance to KRAS G12C inhibitors has emerged in clinical studies.